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As cancer epidemiologists, we 
read the article by Baumann et al.1 
with great interest. We praise Baumann 
for producing a body of literature on 
mesothelioma and exposure to natu-
ral-occurring asbestos (NOA).2–4 The 
recent discovery of NOA in Southern 
Nevada has raised our interest in the 
surveillance of mesothelioma in the 
region.
Unfortunately, in our opinion, 
the methodology used was inappro-
priate for the stated aim of the study: 
“to test that malignant mesothelioma 
is increased in Southern Nevada in a 
pattern consistent with environmen-
tal exposure.” The proper indicator of 
risk in a population or a subpopula-
tion is the incidence rate (gender spe-
cific, age adjusted, and/or age specific). 
Proportions or sex ratios restricted to 
mesothelioma deaths are not appropri-
ate measures of risk because they do 
not account for the underlying popu-
lation pool (and the concept of risk in 
epidemiology) from which the cases 
arise. For instance, a male to female sex 
ratio can be elevated just by virtue of a 
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comments on our recent article report-
ing on a multicenter cohort of 68 
patients with solitary fibrous tumors 
of the pleura (SFTP), who were ana-
lyzed for the complete course of the 
disease in a routine practice setting.1 
We acknowledge that our recurrence 
rate of 30% in nonmetastatic dis-
ease was higher than that previously 
reported in surgical series, includ-
ing that by Tapias et al.2 (14%). We 
hypothesize this may be related to (1) 
a more limited enrollment period (12 
years from 2000 to 2012, versus 33 
years from 1977 to 2010 in the Tapias 
series) together with (2) a prolonged 
median follow-up of 13 years and (3) 
the recruitment of cases from medi-
cal oncology services, at an advanced 
stage of the disease then requiring 
chemotherapy treatment.1 We agree 
that incomplete resection may have 
contributed to this higher recurrence 
rate, as five patients—four stage II 
tumors, one stage III tumor—had 
R1 resection, and two patients—
both stage III—had R2 resection. 
We believe this reflects routine prac-
tice, as other surgical series simi-
larly reported incomplete resection 
to occur in 7% to 11% of malignant 
SFTP.3
On the basis of their series of 
59 patients, Tapias et al. propose 
a scoring system to predict SFTP 
recurrences; four of the six variables 
of this scoring are actually common 
with that of the England/de Perrot 
staging, including structure, mitotic 
activity, cellularity, and presence of 
necrosis.2 Of note, Tapias et al. did 
not applied the de Perrot staging to 
their cases, whereas they stated that 
scoring was a superior predictor of 
recurrence.
Comparing our cohort with this 
series, scores had the following distri-
bution: 0 in 15% versus 42% patients, 
1 in 13% versus 19%, 2 in 28% versus 
19%, 3 in 19% versus 12%, 4 in 7% 
versus 5%, 5 in 9% versus 3%, and 
6 points in 9% versus 0%. Scoring, 
although correlating with the de Perrot 
stage (p < 0.001), was also a sig-
nificant predictor of recurrence-free 
survival (p = 0.007): 3-year, 5-year, 
10-year, and 15-year recurrence-free 
survival rates were 40%, 31%, 25%, 
and 25%, respectively, for a score 
≥3, and 88%, 70%, 58%, and 58%, 
respectively, for a score <3. These fig-
ures are far lower than that reported in 
the original series by Tapias et al.—
80%, 69%, 23%, and 23% for a score 
≥3 and 100% for a score of <3—and 
in a more recent validation cohort.5 
This reflects the higher aggressive-
ness of our cases that would be even 
more appreciated using the proposed 
6-class score, which may be even 
more relevant for advanced malignant 
cases. Whether these analyses are rel-
evant to drive perioperative manage-
ment still remains to be determined, 
especially because the efficacy of 
adjuvant treatment is limited, as high-
lighted in our cohort.
Ultimately, such major differ-
ences between reported series of TFSPs 
emphasize the need for multicenter col-
laboration to develop prospective obser-
vational cohorts of consecutive patients, 
what remains challenging given the 
wide range of aggressiveness of the dis-
ease, the long-term survival of patients, 
and the multidisciplinary management 
from initial presentation to recurrent 
disease.
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low number of male cases rather than 
an actual increased absolute number 
among females. Likewise, a high pro-
portion of cases in younger populations 
may be the result of lower numbers in 
the older groups because of low inci-
dence, or simply because of a smaller 
population pool. We reviewed the ref-
erences provided, and there is no sci-
entific consensus on the use of the sex 
ratio and the proportion under 55 years 
of age as indicators of environmental 
(nonoccupational) exposure to asbestos 
or NOA.
The authors presented pro-
portions, ratios, incidence rates for 
2006–2010, and then mortality rates 
for 1999–2010. Multiple comparisons 
follow but with an inconsistent lists 
of states, first with states of low inci-
dence (45 states, excluding 5 states 
classified as high incidence states), 
followed by mortality comparisons 
with 35 states without asbestos indus-
try. Only one state, Alaska, has both 
high incidence and asbestos indus-
try. With this much information from 
various sources, it is difficult to fully 
understand the occurrence of meso-
thelioma in Nevada and in its south-
ern counties (Clark and Nye).
These proportions, ratios, and 
inconsistent comparisons are used 
as evidence, which is then summa-
rized as “elevated rates,” thus convey-
ing the notion of an increased risk of 
mesothelioma for Southern Nevada. 
Simultaneously, the text points to an 
ecological link between mesothelioma 
and increased environmental exposure 
in our region. In referring to a past 
study, causality (a strong concept epi-
demiologists reserve to studies using 
individual level data) is mentioned 
between NOA and mesothelioma, 
when the evidence provided is mostly 
ecological.2 Also, the presented num-
bers do not add up correctly: a total 
of 31,526 deaths in the 50 U.S. states 
is mentioned, but in Table 2, the sum 
of 49 other states and Clark and Nye 
counties, 31,545, already exceeds the 
total sum.
Mesothelioma is rare, and the 
low numbers with high variability 
across geographic region make the 
statistical analysis difficult. Because 
of its very poor prognosis, the inci-
dence and mortality rates of meso-
thelioma are very similar. Using the 
in-state mortality files (192 deaths 
during 1999–2010) and the Centers 
for Disease Control and Prevention 
wonder data5 (29,663 deaths), we 
measured the risk for mesothelioma, 
reproducing the categories Baumann 
refers as markers for NOA exposure 
(Table 1).
The risk for mesothelioma is not 
increased in Southern Nevada for any 
category analyzed. The low sex ratio 
found by Baumann results from a sig-
nificantly lower than average mortal-
ity among males in Southern Nevada 
and not from an increased mortality or 
risk for females. Likewise, the risk is 
not significantly raised for those aged 
0 to 54 years old. Moreover, the choice 
of 55 years as a cutoff to characterize 
younger cases is questionable. For the 
immediately younger (0–49) and older 
age groups (0–59), the risk in Nevada 
is fundamentally the same as in the 
United States. In conclusion, we have 
strong reservations over the evidence 
presented on the risk of mesothelioma 
in Nevada in this article and suggest 
the use of improved methodology to 
assess the relationship between NOA 
exposure and mesothelioma.
Paulo S. Pinheiro, MD, MSc, PhD
Hongbin Jin, MPH, RN
Epidemiology and Biostatistics
School of Community Health Sciences
University of Nevada Las Vegas
Las Vegas, Nevada 
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TABLE 1.  Mortality Rates for Malignant Mesothelioma 1999–2010 with Corresponding 95% Confidence Intervals
All Age Groups Combined Younger Age Groups, Sexes Combined
Male Female 0–49 Years Old 0–54 Years Old 0–59 Years Old
US-49a 1.60 (1.58–1.62) 0.29 (0.28–0.29) 0.04 (0.04–0.04) 0.07 (0.06–0.07) 0.11 (0.11–0.11)
US-34b 1.57 (1.55–1.60) 0.29 (0.28–0.30) 0.04 (0.03–0.04) 0.07 (0.06–0.07) 0.11 (0.11–0.11)
Nevada 1.34 (1.12–1.59) 0.30 (0.22–0.40) 0.04 (0.02–0.08) 0.09 (0.06–0.14) 0.12 (0.08–0.17)
Southern Nevadac 1.16 (0.92–1.43) 0.33 (0.23–0.47) 0.05 (0.02–0.10) 0.09 (0.05–0.15) 0.11 (0.07–0.18)
Other Nevada 1.78 (1.33–2.33) 0.21 (0.10–0.41) 0.02 (0.00–0.10) 0.09 (0.03–0.19) 0.14 (0.07–0.26)
Rates are per 100,000 and age adjusted for the 2000 U.S. standard population.
aU.S. states except Nevada.
bU.S. states excluding Nevada and 15 states with commercial asbestos production.
cClark and Nye counties.
